Hematopoietic Stem Cells Transplantation Market Trends

Growth Drivers

Rising Elderly Population – Hematopoietic cell transplant (HCT) is increasingly being referred by physicians to older adults for the treatment of malignancies since age is no longer seen as a complete barrier to hematopoietic stem cell transplantation (HSCT). As per the World Health Organization, the worldwide geriatric population was over 524 million in 2010 and this number is expected to cross 2 billion by 2050.
Growing Incidence of Lymphoma- Stem cell transplantation is frequently used to treat blood malignancies such as Hodgkin lymphoma and non-Hodgkin lymphoma by replacing damaged bone marrow cells with healthy stem cells.
Increasing Prevalence of Sickle Cell Disorders- The sole treatment for individuals with sickle cell disease (SCD) is hematopoietic stem cell transplantation (HSCT) since it entails transferring healthy cells from a sibling or sister who qualifies to replace the aberrant stem cells that are present in the bone marrow.
Surging Research & Development Activities- For instance, in 2020, Gamida Cell announced that it had completed enrollment in the Phase 3 clinical trial of its hematopoietic stem cell product.

Challenges

Adverse Effected Resulting From Hematopoietic Stem Cells Transplantation - Numerous adverse effects of an HSCT transplant resemble those that are frequently experienced after receiving radiation and chemotherapy including greater risk of infection, relapse in illness, death from CMV infection, and graft-versus-host disease (GVHD) which may result from age, baseline performance condition, the source of the stem cell transplant, the kind and severity of the preparative regimen, and many other factors. Moreover, patients who had severe marrow fibrosis before transplantation may also experience graft failure which is frequently linked to a cancer recurrence as the leukemic cells may prevent the transplanted cells from growing.
High Cost of Hematopoietic Stem Cells Transplantation Treatment Owing to the Complexity of the Procedure
Limited Availability of Matched Donors As it Involves Intricate Tissue Typing and HLA Matching

Hematopoietic Stem Cells Transplantation Market: Key Insights

Base Year	2024
Forecast Year	2025-2037
CAGR	9.7%
Base Year Market Size (2024)	USD 3.05 billion
Forecast Year Market Size (2037)	USD 10.16 billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of hematopoietic stem cells transplantation is evaluated at USD 3.29 billion.

The hematopoietic stem cells transplantation market size was over USD 3.05 billion in 2024 and is expected to exceed USD 10.16 billion by the end of 2037, growing at over 9.7% CAGR during the forecast period i.e., between 2025-2037. Rising prevalence of leukemia and the growing advancements in stem cell transplantation technology will drive the market growth.

North America industry is likely to dominate majority revenue share 40% by 2037, impelled by presence of major key players in the region.

The major players in the market are Escape Therapeutics, Inc., Regen BioPharma, Inc., ThermoGenesis Holdings, Inc., CSG-BIO Company, Inc. (CellSave), CBR Systems, Inc., Pluristem Inc., Global Cord Blood Corporation, ViaCord, LLC, Cynata Therapeutics Limited, and others.

Hematopoietic Stem Cells Transplantation Market Trends